Black Rock Inc. Invitae Corp Transaction History

Black Rock Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.42 - $0.72 $646,466 - $1.11 Million	-1,539,207 Reduced 7.4%	19,258,772 $12.1 Million
Q3 2023 Nov 13, 2023	SELL	$0.6 - $1.53 $315,393 - $804,252	-525,655 Reduced 2.47%	20,797,979 $12.5 Million
Q2 2023 Aug 11, 2023	BUY	$1.05 - $1.63 $634,285 - $984,652	604,081 Added 2.92%	21,323,634 $24.1 Million
Q1 2023 May 12, 2023	SELL	$1.2 - $2.73 $1.26 Million - $2.87 Million	-1,051,607 Reduced 4.83%	20,719,553 $28 Million
Q4 2022 Feb 13, 2023	BUY	$1.71 - $3.61 $920,737 - $1.94 Million	538,443 Added 2.54%	21,771,160 $40.5 Million
Q3 2022 Nov 14, 2022	BUY	$1.9 - $8.63 $110,357 - $501,256	58,083 Added 0.27%	21,232,717 $52.2 Million
Q2 2022 Aug 12, 2022	BUY	$2.13 - $9.01 $3.84 Million - $16.2 Million	1,802,406 Added 9.3%	21,174,634 $51.7 Million
Q1 2022 May 12, 2022	BUY	$6.28 - $15.59 $11.9 Million - $29.4 Million	1,887,443 Added 10.79%	19,372,228 $154 Million
Q4 2021 Feb 10, 2022	BUY	$14.7 - $28.67 $10 Million - $19.5 Million	681,198 Added 4.05%	17,484,785 $267 Million
Q3 2021 Nov 09, 2021	SELL	$24.31 - $33.6 $25.5 Million - $35.3 Million	-1,049,108 Reduced 5.88%	16,803,587 $478 Million
Q2 2021 Aug 11, 2021	BUY	$26.09 - $40.4 $466 Million - $721 Million	17,852,695 New	17,852,695 $602 Million

1.92M

Ticker NVTA
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 235,266,000
Description
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.